It is unlikely that the plasma levels that  also claimed chronic administration. Similarly, another study that PDE4 inhibitors in concentrations, the pharmacologically relevant delay Ht delay apoptosis, neutrophils and eosinophils, an effect that, when combined with factor b2 adrenoceptor agonists increased. However, as these results into practice, especially when it is combined with the Elvitegravir EVG bronchodilator drugs are rt yet clarified. Clinical data suggest that PDE4 inhibitors suppress and not various MAY BE airway inflammation. PDE4 inhibitors and the future While there is reason to be optimistic about the m Possible therapeutic use of PDE4 inhibitors for the treatment of respiratory diseases such as asthma and COPD, it is clear that further improvement is required. Strategies to improve risk-benefit ratio for any household, it will be important when this class of drugs is widespread.
The therapeutic window for anti-inflammatory action of these drugs and side effects such as nausea and vomiting is probably not large enough cilomilast, and k can limit the use of roflumilast in asthma. It PDE4 inhibitors in development, which seems to lack the emetic IPL512602 important, and although the molecular basis of which has not yet been ffentlicht ver. Most of the PDE4 inhibitors are formed in the development for more po administration but inhaled would PDE4 inhibitor to deliver directly to minimize target cells in the lung and systemic absorption, as in the case of AWD 12 281 or glyoxylic Acid amide UK 500 001 but clinical trials in respiratory diseases have so far disappointed uschend. However, k Nnte the development of a potent inhibitor of PDE4 long-acting inhaled offer a L Solution for the question of vomiting and nausea.
Another approach w re Using antisense oligodeoxynucleotides targeting PDE4, which are administered by inhalation k Nnte and positive results correspond allergic in the successful targeting of adenosine A1 receptor in a rabbit model of inflammation, shows the potential of the approach. Another reason for targeting PDE4 alone completely Constantly l Sen airway inflammation is the fact that it is possible, other types of PDE in structural and inflammatory cells in the lung in place and thus targeting multiple PDE enzymes necessary for an optimal anti- inflammatory effect. For example, the macrophage is considered a critical cell type in the pathogenesis of COPD, but the activity of t these cells only slightly Ma E inhibited by PDE4 inhibitors and potential functional involvement of PDE3 and PDE7 not these cells completely Constantly be ignored.
The inhibitory effect of PDE4 inhibitors on the cellular Activity re t Significantly by T lymphocytes and macrophages in the presence of selective inhibitors CD8t PDE7 erh Ht. PDE3 and PDE4 inhibitor also combined into a single molecule has the advantage of providing a bronchodilator and anti-inflammatory substance. Moreover, it is probable that the retention of the inhibitor in the lungs may be necessary, the anti-inflammatory activity of t Keep in the air passages. Conclusion A number of clinical trials that are the efficacy of PDE4 inhibitors for the treatment of respiratory diseases such as asthma and COPD m Moderately successful.